Aberrantly methylated genes in pancreatic cancer
AssigneeThe Johns Hopkins University
InventorsMichael G. Goggins, Norihiro Sato
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject.
Claims9
An amplification primer pair, comprising a forward primer and a reverse primer as set forth in SEQ ID NOS:
- 5 to 16, 21 to 56, and 61 to 64, wherein the amplification primer pair can amplify a portion of a gene, or associated regulatory region of the gene, selected from the group consisting of reprimo, CLDN5, DR3, LDOC1, LHX1, NEFH, NPTX2, PIG11, SARP2, ST14, SMARCA1, TJP2, and WNT7A, or a combination thereof.
A kit useful for the detection of pancreatic carcinoma in a subject comprising:
- a) carrier means compartmentalized to receive a sample therein;
- b) one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primers are selected from SEQ ID NOS:
- 5 to 16, 21 to 56, and 61 to 64.
Dependencies are inferred from the claim text.